Literature DB >> 1374842

Epitope mapping of anti-breast and anti-ovarian mucin monoclonal antibodies.

P X Xing1, J Prenzoska, I F McKenzie.   

Abstract

Anti-breast cancer antibodies (BC2, HMPV and 4B6) and an anti-ovarian cancer antibody (OM1) were found to react with mucins--indeed with the protein core encoded by the MUC1 gene. This gene contains a VNTR (variable number of tandem repeats) encoding a 60 bp (= 20 amino acids) repeat sequence and within this amino acid sequence SAPDTRPAP was predicted, by hydrophilicity analysis, to be the immunogenic peptide sequence. The four antibodies were shown to react with MUC1 VNTR encoded peptides in direct binding and inhibition studies. The precise reactivity of the 4 mAbs was mapped using ELISA in both solid and liquid phase, and demonstrated the epitopes to be: APDTR (BC2 and HMPV), PDTR (4B6) and DTRPA (OM1). By using the pepscan method, the epitopes were shorter (PDTR, DTR and DTRP). However when these short peptides (except DTR) were synthesized they did not react; flanking amino acids are needed for the epitopes. Clearly several different methods should be used to define the reactive epitope. Within (S)APDTR, major amino acid substitutions could be made--even of three to four amino acids without altering antibody binding, provided that P and R were not substituted. It was of interest that an anti-ovarian cancer antibody gave similar anti-peptide reactions to the anti-breast cancer antibodies; apparently MUC1 peptides in ovarian cancer are the same as in breast cancer.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1374842     DOI: 10.1016/0161-5890(92)90201-8

Source DB:  PubMed          Journal:  Mol Immunol        ISSN: 0161-5890            Impact factor:   4.407


  8 in total

1.  Form and pattern of MUC1 expression on T cells activated in vivo or in vitro suggests a function in T-cell migration.

Authors:  Isabel Correa; Tim Plunkett; Anda Vlad; Arron Mungul; Jessica Candelora-Kettel; Joy M Burchell; Joyce Taylor-Papadimitriou; Olivera J Finn
Journal:  Immunology       Date:  2003-01       Impact factor: 7.397

2.  Natural human anti-Gal alpha(1,3)Gal antibodies react with human mucin peptides.

Authors:  M S Sandrin; H A Vaughan; P X Xing; I F McKenzie
Journal:  Glycoconj J       Date:  1997-01       Impact factor: 2.916

Review 3.  MUC1 (CD227): a multi-tasked molecule.

Authors:  Vasso Apostolopoulos; Lily Stojanovska; Sharron E Gargosky
Journal:  Cell Mol Life Sci       Date:  2015-08-21       Impact factor: 9.261

4.  Antibody and T cell responses of patients with adenocarcinoma immunized with mannan-MUC1 fusion protein.

Authors:  V Karanikas; L A Hwang; J Pearson; C S Ong; V Apostolopoulos; H Vaughan; P X Xing; G Jamieson; G Pietersz; B Tait; R Broadbent; G Thynne; I F McKenzie
Journal:  J Clin Invest       Date:  1997-12-01       Impact factor: 14.808

5.  The cell surface mucin MUC1 limits the severity of influenza A virus infection.

Authors:  J L McAuley; L Corcilius; H-X Tan; R J Payne; M A McGuckin; L E Brown
Journal:  Mucosal Immunol       Date:  2017-03-22       Impact factor: 7.313

6.  Homology modeling and molecular dynamics simulations of MUC1-9/H-2K(b) complex suggest novel binding interactions.

Authors:  Athanassios Stavrakoudis; Ioannis G Tsoulos; Katalin Uray; Ferenc Hudecz; Vasso Apostolopoulos
Journal:  J Mol Model       Date:  2010-11-16       Impact factor: 1.810

7.  Sequence-Specific Mucins for Glycocalyx Engineering.

Authors:  Hao Pan; Marshall J Colville; Nitin T Supekar; Parastoo Azadi; Matthew J Paszek
Journal:  ACS Synth Biol       Date:  2019-10-02       Impact factor: 5.110

8.  Apical MUC1 expression revealed on the foveolar epithelium in H. pylori gastritis.

Authors:  M Rashid; A S Teixeira; U Qureshi; S P Pereira; M R Novelli; D M Swallow
Journal:  Br J Cancer       Date:  2013-02-14       Impact factor: 7.640

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.